+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2020

  • ID: 5146863
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 163 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Ansun Biopharma Inc
  • BlueWillow Biologics Inc
  • Emergent BioSolutions Inc
  • ILiAD Biotechnologies LLC
  • NanoViricides Inc
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2020, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 6, 2, 18 and 4 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 4 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Ansun Biopharma Inc
  • BlueWillow Biologics Inc
  • Emergent BioSolutions Inc
  • ILiAD Biotechnologies LLC
  • NanoViricides Inc
  • MORE
Introduction
  • Influenza A Virus, H3N2 Subtype Infections - Overview
  • Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment

Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
  • Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
  • Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
  • Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H2 2020
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, H2 2020
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Alla Chem LLC, H2 2020
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Allergy Therapeutics Plc, H2 2020
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2020
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • AbbVie Inc
  • Adimmune Corp
  • Alla Chem LLC
  • Allergy Therapeutics Plc
  • Ansun Biopharma Inc
  • Aphios Corp
  • AstraZeneca Plc
  • AusBio Ltd
  • BiondVax Pharmaceuticals Ltd
  • BlueWillow Biologics Inc
  • Brandenburg Antiinfektiva GmbH
  • Changchun Bcht Biotechnology Co Ltd
  • Chicago Biosolutions Inc
  • Cidara Therapeutics Inc
  • ContraFect Corp
  • Emergent BioSolutions Inc
  • FluGen Inc
  • Gamma Vaccines Pty Ltd
  • i2 Pharmaceuticals Inc
  • ILiAD Biotechnologies LLC
  • Inovio Pharmaceuticals Inc
  • InvVax Inc
  • Jiangsu Ab&b Biotechnology Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Medicago Inc
  • NanoViricides Inc
  • New Amsterdam Sciences Inc
  • Novavax Inc
  • PrEP Biopharm Ltd
  • Sanofi
  • Sciogen Inc
  • Seqirus Ltd
  • Serum Institute of India Ltd
  • Vacthera BioTech GmbH
Note: Product cover images may vary from those shown
Adroll
adroll